dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
Published 4 years ago • 208 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:16
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
2:13
dr. mesa on the efficacy of fedratinib in patients with myelofibrosis and low platelet counts
-
0:56
dr. saint fleur-lominy on the use of ruxolitinib versus fedratinib in mpns
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
1:10
dr. bradley on the utility of ruxolitinib in myelofibrosis and polycythemia vera
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
1:27
dr. kuykendall on choosing ruxolitinib or fedratinib in myelofibrosis
-
7:43
the role of fedratinib in myelofibrosis
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
1:06
fedratinib: mpn-associated myelofibrosis
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
2:22
dr. scherber discusses ruxolitinib failure in myelofibrosis